Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis

Journal of Molecular Psychiatry

Shiva M Singh¹  Richard O’Reilly²  N Rajakumar²  Benjamin I Laufer¹  Christina A Castellani¹  Melkaye G Melka¹ 

[1] Department of Biology, Molecular Genetics Unit, Western Science Centre, The University of Western Ontario, London, Ontario N6A 5B7, Canada;Department of Psychiatry, The University of Western Ontario, London, Ontario N6A 5B7, Canada

关键词: Epigenetics;    DNA methylation;    Olanzapine;    Psychosis;    Dopamine;   

Others  :  819954
DOI  :  10.1186/2049-9256-1-19

 received in 2013-09-06, accepted in 2013-10-16,  发布年份 2013

【 摘 要 】

Background

The dopamine (DA) hypothesis of schizophrenia proposes the mental illness is caused by excessive transmission of dopamine in selected brain regions. Multiple lines of evidence, including blockage of dopamine receptors by antipsychotic drugs that are used to treat schizophrenia, support the hypothesis. However, the dopamine D2 receptor (DRD2) blockade cannot explain some important aspects of the therapeutic effect of antipsychotic drugs. In this study, we hypothesized that antipsychotic drugs could affect the transcription of genes in the DA pathway by altering their epigenetic profile.

Methods

To test this hypothesis, we examined the effect of olanzapine, a commonly used atypical antipsychotic drug, on the DNA methylation status of genes from DA neurotransmission in the brain and liver of rats. Genomic DNA isolated from hippocampus, cerebellum, and liver of olanzapine treated (n = 2) and control (n = 2) rats were analyzed using rat specific methylation arrays.

Results

Our results show that olanzapine causes methylation changes in genes encoding for DA receptors (dopamine D1 receptor, dopamine D2 receptor and dopamine D5 receptor), a DA transporter (solute carrier family 18 member 2), a DA synthesis (differential display clone 8), and a DA metabolism (catechol-O-methyltransferase). We assessed a total of 40 genes in the DA pathway and found 19 to be differentially methylated between olanzapine treated and control rats. Most (17/19) genes showed an increase in methylation, in their promoter regions with in silico analysis strongly indicating a functional potential to suppress transcription in the brain.

Conclusion

Our results suggest that chronic olanzapine may reduce DA activity by altering gene methylation. It may also explain the delayed therapeutic effect of antipsychotics, which occurs despite rapid dopamine blockade. Furthermore, given the common nature of epigenetic variation, this lends insight into the differential therapeutic response of psychotic patients who display adequate blockage of dopamine receptors.

【 授权许可】

   
2013 Melka et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Madras BK: History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia. J Hist Neurosci 2013, 22:62-78.
• [2]Seeman P, Dopamine receptor sequences: Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992, 7:261-284.
• [3]Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002, 47:27-38.
• [4]Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 2010, 4:56-73.
• [5]Corripio I, Escarti MJ, Portella MJ, Perez V, Grasa E, Sauras RB, Alonso A, Safont G, Camacho MV, Duenas R, Arranz B, San L, Catafau AM, Carrio I, Alvarez E: Density of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT study. Eur Neuropsychopharmacol 2011, 21:861-866.
• [6]Yeh TK, Hu CY, Yeh TC, Lin PJ, Wu CH, Lee PL, Chang CY: Association of polymorphisms in BDNF, MTHFR, and genes involved in the dopaminergic pathway with memory in a healthy Chinese population. Brain Cogn 2012, 80:282-289.
• [7]Manschreck TC, Boshes RA: The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007, 15:245-258.
• [8]Kapur S, Barsoum SC, Seeman P: Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ. Neuropsychopharmacology 2000, 23:595-598.
• [9]Karagianis JL, LeDrew KK, Walker DJ: Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. Curr Med Res Opin 2003, 19:473-480.
• [10]Mancama D, Arranz MJ, Kerwin RW: Pharmacogenomics of psychiatric drug treatment. Curr Opin Mol Ther 2003, 5:642-649.
• [11]Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, Daskalakis ZJ: Antipsychotics, dopamine D(2) receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophr Res 2012, 140:214-220.
• [12]Singh SM, Murphy B, O’Reilly RL: Involvement of gene-diet/drug interaction in DNA methylation and its contribution to complex diseases: from cancer to schizophrenia. Clin Genet 2003, 64:451-460.
• [13]Petronis A: The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biol Psychiatry 2004, 55:965-970.
• [14]Roth TL, Lubin FD, Sodhi M, Kleinman JE: Epigenetic mechanisms in schizophrenia. Biochim Biophys Acta 2009, 1790:869-877.
• [15]Dempster E, Viana J, Pidsley R, Mill J: Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future. Schizophr Bull 2013, 39:11-16.
• [16]Pirooznia M, Nagarajan V, Deng Y: GeneVenn - a web application for comparing gene lists using Venn diagrams. Bioinformation 2007, 1:420-422.
• [17]Bao L, Zhou M, Cui Y: CTCFBSDB: a CTCF binding site database for characterization of vertebrate genomic insulators. Nucleic Acids Res 2008, 36:D83-D87.
• [18]Deng C, Lian J, Pai N, Huang XF: Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol 2012, 26:1271-1279.
• [19]Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, Theodoropoulou P, Fernandez LG, Ucok A, Tessier C, Bergmans P, Hoeben D: Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol 2012, 32:449-457.
• [20]Bardgett ME, Humphrey WM, Csernansky JG: The effects of excitotoxic hippocampal lesions in rats on risperidone- and olanzapine-induced locomotor suppression. Neuropsychopharmacology 2002, 27:930-938.
• [21]Grace AA: Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 2011, 62:1342-1348.
• [22]Jun H, Mohammed Qasim Hussaini S, Rigby MJ, Jang MH: Functional role of adult hippocampal neurogenesis as a therapeutic strategy for mental disorders. Neural Plast 2012, 2012:1-20.
• [23]Eisenberg DP, Ianni AM, Wei SM, Kohn PD, Kolachana B, Apud J, Weinberger DR, Berman KF: Brain-derived neurotrophic factor (BDNF) Val(66)Met polymorphism differentially predicts hippocampal function in medication-free patients with schizophrenia. Mol Psychiatry 2013, 18(6):713-720.
• [24]Donohoe G, Walters J, Morris DW, Quinn EM, Judge R, Norton N, Giegling I, Hartmann AM, Moller HJ, Muglia P, Williams H, Moskvina V, Peel R, O’Donoghue T, Owen MJ, O’Donovan MC, Gill M, Rujescu D, Corvin A: Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Arch Gen Psychiatry 2009, 66:1045-1054.
• [25]Green EK, Grozeva D, Jones I, Jones L, Kirov G, Caesar S, Gordon-Smith K, Fraser C, Forty L, Russell E, Hamshere ML, Moskvina V, Nikolov I, Farmer A, McGuffin P, Holmans PA, Owen MJ, O’Donovan MC, Craddock N, Consortium Wellcome Trust Case Control: The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 2010, 15:1016-1022.
• [26]Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH, Egan MF, Huffaker SS, Mattay VS, Kolachana B, Kleinman JE, Weinberger DR: Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 2007, 117:672-682.
• [27]Pal P, Mihanovic M, Molnar S, Xi H, Sun G, Guha S, Jeran N, Tomljenovic A, Malnar A, Missoni S, Deka R, Rudan P: Association of tagging single nucleotide polymorphisms on 8 candidate genes in dopaminergic pathway with schizophrenia in Croatian population. Croat Med J 2009, 50:361-369.
• [28]Razin A, Cedar H: DNA methylation and gene expression. Microbiol Rev 1991, 55:451-458.
• [29]Feng W, Dong Z, He B, Wang K: Analysis method of epigenetic DNA methylation to dynamically investigate the functional activity of transcription factors in gene expression. BMC Genomics 2012, 13:532-2164. 13-532 BioMed Central Full Text
• [30]Loo SK, Rich EC, Ishii J, McGough J, McCracken J, Nelson S, Smalley SL: Cognitive functioning in affected sibling pairs with ADHD: familial clustering and dopamine genes. J Child Psychol Psychiatry 2008, 49:950-957.
• [31]Centonze D, Grande C, Saulle E, Martin AB, Gubellini P, Pavon N, Pisani A, Bernardi G, Moratalla R, Calabresi P: Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 2003, 23:8506-8512.
• [32]Hansen N, Manahan-Vaughan D: Dopamine D1/D5 Receptors Mediate Informational Saliency that Promotes Persistent Hippocampal Long-Term Plasticity. Cereb Cortex 2012. 10.1093/cercor/bhs362
• [33]van Os J, Kapur S: Schizophrenia. Lancet 2009, 374:635-645.
• [34]Van Den Bossche MJ, Strazisar M, Cammaerts S, Liekens AM, Vandeweyer G, Depreeuw V, Mattheijssens M, Lenaerts AS, De Zutter S, De Rijk P, Sabbe B, Del-Favero J: Identification of rare copy number variants in high burden schizophrenia families. Am J Med Genet B Neuropsychiatr Genet 2013, 162:273-282.
• [35]Lee D, Huang W, Lim AT: Dopamine induces a biphasic modulation of hypothalamic ANF neurons: a ligand concentration-dependent effect involving D5 and D2 receptor interaction. Mol Psychiatry 2000, 5:39-48.
• [36]Popendikyte V, Laurinavicius A, Paterson AD, Macciardi F, Kennedy JL, Petronis A: DNA methylation at the putative promoter region of the human dopamine D2 receptor gene. Neuroreport 1999, 10:1249-1255.
• [37]Roig B, Virgos C, Franco N, Martorell L, Valero J, Costas J, Carracedo A, Labad A, Vilella E: The discoidin domain receptor 1 as a novel susceptibility gene for schizophrenia. Mol Psychiatry 2007, 12:833-841.
• [38]Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R, Di Giorgio A, Taurisano P, Papp A, Pinsonneault J, Wang D, Nardini M, Popolizio T, Sadee W: Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 2009, 132:417-425.
• [39]Anier K, Malinovskaja K, Pruus K, Aonurm-Helm A, Zharkovsky A, Kalda A: Maternal separation is associated with DNA methylation and behavioural changes in adult rats. Eur Neuropsychopharmacol 2013. 10.1016/j.euroneuro.2013.07.012
• [40]Singh S, Li SS: Epigenetic effects of environmental chemicals bisphenol a and phthalates. Int J Mol Sci 2012, 13:10143-10153.